Blueprint Medicines Slumps to 21st in Daily Rankings Amid Sanofi Acquisition

On June 3, 2025, Blueprint Medicines Corporation (BPMC) experienced a significant drop in trading volume, with a total turnover of $25.68 billion, marking a 56.7% decrease from the previous day. This decline placed BPMC at the 21st position in the daily stock market rankings. The stock price of Blueprint Medicines Corporation (BPMC) decreased by 0.15%.

Sanofi, a French pharmaceutical company, has agreed to acquire Blueprint Medicines Corporation for up to $9.5 billion. This acquisition aims to strengthen Sanofi's position in the field of rare immunology diseases. The deal includes the acquisition of Blueprint's drug Ayvakit, which is approved in the U.S. and the EU for treating systemic mastocytosis and other KIT-driven diseases. Sanofi will pay $129.00 per share in cash, with potential milestone payments, making the total equity value approximately $9.1 billion. This acquisition is part of Sanofi's strategy to expand its immunology pipeline and access to rare disease treatments.

Sanofi's CEO, Paul Hudson, highlighted that the acquisition of Blueprint Medicines is a strategic move to enhance their rare and immunology portfolios. He also mentioned that Sanofi still has the capacity for further acquisitions, indicating the company's continued interest in expanding its portfolio through strategic investments. The acquisition of Blueprint Medicines is the latest in a series of moves by Sanofi to bolster its position in the biopharmaceutical industry.